Severe Acute Respiratory Syndrome Coronavirus Infection Market

Market Overview:

The 7 major severe acute respiratory syndrome coronavirus infection markets reached a value of US$ 21.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 68.5 Billion by 2034, exhibiting a growth rate (CAGR) of 11.14% during 2024-2034.

The severe acute respiratory syndrome coronavirus infection market has been comprehensively analyzed in IMARC's new report titled "Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Severe acute respiratory syndrome coronavirus infection, commonly known as SARS-CoV, is a viral pulmonary illness caused by the SARS coronavirus. The primary transmission mode of this ailment is through respiratory droplets when an infected individual sneezes or coughs. It can also spread by contacting surfaces contaminated with the virus and then touching the face. The common symptoms of the disorder include high fever, cough, shortness of breath, difficulty breathing, chills, body aches, headaches, diarrhea, nausea, vomiting, etc. In severe cases, individuals suffering from this disease may also experience pneumonia, respiratory distress, hypoxemia, or multiple organ failure. The diagnosis of SARS-CoV infection typically requires a combination of clinical presentation, medical history review, and a physical examination. Polymerase chain reaction testing is also used to detect the genetic material (RNA) of the virus in respiratory samples, such as nasal swabs, throat swabs, or sputum. The healthcare provider may further conduct chest X-rays and computed tomography scans to assess lung involvement and identify any characteristic patterns associated with the disease, like ground-glass opacities or consolidation.

The increasing prevalence of viral shedding through respiratory droplets when an infected individual sneezes, coughs, talks, or breathes heavily in close proximity to others is primarily driving the severe acute respiratory syndrome coronavirus infection market. In addition to this, the expanding geriatric population, who have weakened immunity, along with pre-existing health conditions like cardiovascular disease and diabetes, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and monoclonal antibodies, to modulate the production and activity of pro-inflammatory cytokines is further bolstering the market growth. Apart from this, the inflating application of respiratory physiotherapy, since it involves techniques that help in clearing secretions from the lungs, improving pulmonary function, and promoting better breathing in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation procedures, which provide circulatory support by ensuring adequate blood flow to vital organs, is expected to drive the severe acute respiratory syndrome coronavirus infection market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the severe acute respiratory syndrome coronavirus infection market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for severe acute respiratory syndrome coronavirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the severe acute respiratory syndrome coronavirus infection market in any manner.

Key Highlights:

• The majority of patients diagnosed with severe acute respiratory syndrome coronavirus infection were noted to be previously healthy individuals aged 25 to 70 years.
• Several suspected cases of severe acute respiratory syndrome coronavirus infection have been recorded in children under the age of 15.
• The case fatality rate among patients with sickness, fulfilling the new WHO case criteria for probable and suspected cases of severe acute respiratory syndrome coronavirus infection, is around 3%.
• Approximately 75% of COVID-19 deaths in the United States were among people aged 65 and older.
• The highest death rates were among non-Hispanic Black people and non-Hispanic American Indian or Alaska Native people.

Drugs:

Spikevax is a vaccination designed to prevent coronavirus disease 2019 (COVID-19) in people as young as six months old. The original Spikevax comprises elasomeran, a molecule known as messenger RNA (mRNA) containing instructions for creating a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19.

SNG001 is a recombinant interferon (IFN)-β1a formulation administered to the lungs by a nebulizer. IFN-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus.

NA-831 is a tiny pharmacological molecule with neuroprotective properties, which means it can prevent or reduce disease development by halting or decreasing neuronal death. The medication also has neurogenesis and cognitive protective characteristics across a variety of illness types. NA-831 is in Phase 2/3 clinical trials with FDA-approved antiviral medicines Atazanavir and Dexamethasone to treat Covid-19.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the severe acute respiratory syndrome coronavirus infection market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the severe acute respiratory syndrome coronavirus infection market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current severe acute respiratory syndrome coronavirus infection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the severe acute respiratory syndrome coronavirus infection market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the severe acute respiratory syndrome coronavirus infection market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the severe acute respiratory syndrome coronavirus infection market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection across the seven major markets?
• What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with severe acute respiratory syndrome coronavirus infection across the seven major markets?
• What is the size of the severe acute respiratory syndrome coronavirus infection patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of severe acute respiratory syndrome coronavirus infection?
• What will be the growth rate of patients across the seven major markets?
   

Severe Acute Respiratory Syndrome Coronavirus Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for severe acute respiratory syndrome coronavirus infection drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the severe acute respiratory syndrome coronavirus infection market?
• What are the key regulatory events related to the severe acute respiratory syndrome coronavirus infection market?
• What is the structure of clinical trial landscape by status related to the severe acute respiratory syndrome coronavirus infection market?
• What is the structure of clinical trial landscape by phase related to the severe acute respiratory syndrome coronavirus infection market?
• What is the structure of clinical trial landscape by route of administration related to the severe acute respiratory syndrome coronavirus infection market?